Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma FY01: Domestic vs MNCís - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • May 16, 2001

    Pharma FY01: Domestic vs MNCís

    How did the pharma majors perform against each other in FY01? We present a brief comparison between the top 5 domestic vs multinational pharma companies.

    Domestic Pharma Growth in Sales (%) MNC Pharma Growth in Sales (%)
    Ranbaxy 4.50% Glaxo Wellcome 5.50%
    Cipla 37.90% Hoechst Marion Roussel 1.40%
    Sun Pharma 28.70% Pfizer 12.00%
    Wockhardt -2.90% Knoll 14.80%
    Alembic 9.50% SmithKline Beecham -2.10%
    Consolidated growth 13.40% 5.60%

    (Note: Top 5 companies have been on the basis of un-audited results declared)

    Net sales of Top 5 domestic pharma companies has improved by more than 13% (as against industry average of 9-10%). MNC pharma companies under-performed the domestic peers, as consolidated sales grew by mere 5.6%. This could be attributed to obvious reasons viz. relatively older product portfolio and higher DPCO coverage. While MNCís continued to shy away from launching new products, domestic companies were aggressive in product launches. For example Cipla alone launched more than 100 products during the year across various therapeutic segments. It is estimated that MNCís have contributed only 6-7% of total new product launches during FY01. Domestic companies strategy of identifying and exploring new niche therapeutic segments to offer superior products at competitive prices seems to be paying off.

    However, operating margins of Multinational pharma companies inched up further mainly due to relaxation in DPCO during the year. Coming to the operations, most of the MNC pharma companies rationalized their field forces, sold off their real estate and consolidated operations in India. Glaxo, for instance sold off its tail-end brands, as did Hoechst. Indian pharma companies, on the contrary expanded their R&D set ups, filed abbreviated new drug applications (ANDA) to cater to the generic market overseas and bought brands from smaller companies in India.

    The multinationals seem quite sure not to launch their blockbuster products in India till the product patent becomes a reality. The trigger for them in the near term seems to be further relaxation of DPCO as they have strong brands in their stable. On the other hand, Indian companies are gearing up to meet the challenge post product patent regime. Who wins the race post 2005, is anybodyís guess right now, but one thing is certain, Indian pharma scene is all set for a battle royal.



    Equitymaster requests your view! Post a comment on "Pharma FY01: Domestic vs MNCís". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 22, 2017 (Close)